Mymetics Corporation (OTCPK: MYMX)
Health Care · Biotechnology · CH
$—
— today · — 1Y
Mymetics Corporation (OTCPK: MYMX) operates in the Biotechnology industry within the Health Care sector. The company is valued at $46.00 and employs 2 people.
trading between 0.00 and 0.00.
Tweenvest scores Mymetics Corporation across four factors: quality 13/100, value 39/100, growth 0/100. Its strongest factor is value.
MYMX price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- $46.00
- Revenue (TTM)
- $564.14K
- P/E
- —
- EPS
- -76.16
- Dividend yield
- —
- Beta (5Y)
- 2.13
- 52-week high
- $0.00
- 52-week low
- $0.00
- Avg volume (3M)
- —
- Shares outstanding
- 151.88K
- Employees
- 2
- Next earnings
- —
About Mymetics Corporation
Mymetics Corporation is a Swiss biotechnology company dedicated to the research and development of vaccines aimed at preventing infectious and debilitating diseases. Its robust pipeline features several promising vaccine candidates, including those for HIV-1/AIDS, COVID-19, intranasal influenza, respiratory syncytial virus (RSV), malaria, and chikungunya. The company actively collaborates with leading institutions such as the Texas Biomedical Research Institute, the PATH Malaria Vaccine Initiative, and the National Institute of Allergy and Infectious Diseases' Laboratory of Malaria Immunology and Vaccinology, focusing on the development and production of virosome-based vaccine formulations for a malaria transmission-blocking agent. Additionally, Mymetics works with Sanofi Pasteur Biologics, LLC to assess the immunogenicity of influenza vaccines. Founded in 1990, the company was formerly known as ICHOR Corporation, adopting its current name in July 2001, and maintains its base of operations in Epalinges, Switzerland.
- ISIN
- US62856A3005
- Founded
- 1990
- Listed since
- Oct 26, 1999
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Biotechnology companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| AbbVie Inc.NYSE: ABBV | $468.22B | $263.45 | -0.57% |
| Amgen Inc.NasdaqGS: AMGN | $237.52B | $440.67 | +0.31% |
| Gilead Sciences, Inc.NasdaqGS: GILD | $181.18B | $145.57 | -0.38% |
| Vertex Pharmaceuticals IncorporatedNasdaqGS: VRTX | $138.91B | $547.80 | -0.05% |
| Regeneron Pharmaceuticals, Inc.NasdaqGS: REGN | $83.28B | $824.34 | -1.16% |
| argenx SEENXTBR: ARGX | $65.85B | €867.40 | -3.84% |
| Moderna, Inc.NasdaqGS: MRNA | $57.92B | $137.35 | -5.33% |
| CSL LimitedASX: CSL | $57.77B | AU$168.30 | -1.69% |
Figures last refreshed Aug 18, 2026.